Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

1.18
-0.0700-5.60%
Post-market: 1.180.0007+0.06%19:56 EDT
Volume:804.57K
Turnover:962.91K
Market Cap:19.54M
PE:-2.06
High:1.26
Open:1.26
Low:1.11
Close:1.25
Loading ...

MIRA Pharmaceuticals submits IND to FDA for Ketamir-2

TIPRANKS
·
19 Dec 2024

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

ACCESSWIRE
·
19 Dec 2024

Mira Pharmaceuticals Inc - Submits Ind Application to FDA for Ketamir-2

THOMSON REUTERS
·
19 Dec 2024

EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment

Benzinga
·
19 Dec 2024

MIRA Makes Major Strides

Zacks Small Cap Research
·
19 Dec 2024

Mira Pharmaceuticals Inc: Submission of Investigational New Drug (Ind) Application by End of 2024

THOMSON REUTERS
·
10 Dec 2024

Mira Pharmaceuticals Inc: Validates Ketamir-2'S Safety Profile With No Adverse Findings, Paving Way for Ind Submission by Year-End

THOMSON REUTERS
·
10 Dec 2024

Mira Pharmaceuticals Inc: Plans to Initiate Phase I Clinical Trials for Ketamir-2 in Q1 of 2025

THOMSON REUTERS
·
10 Dec 2024

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

ACCESSWIRE
·
10 Dec 2024

EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain

Benzinga
·
10 Dec 2024

MIRA Pharmaceuticals Appoints New Board Member and Chairman

TIPRANKS
·
22 Nov 2024

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

ACCESSWIRE
·
20 Nov 2024

MIRA Continues Solid Financial Management

Zacks Small Cap Research
·
13 Nov 2024

MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials

GuruFocus.com
·
29 Oct 2024

MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain

Benzinga
·
29 Oct 2024

Mira Pharmaceuticals announces preclinical data on Ketamir-2

TIPRANKS
·
28 Oct 2024